These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35169097)

  • 21. Is there a role for targeted medical therapies in patients with craniopharyngiomas?
    Tritos NA
    Future Oncol; 2015; 11(24):3221-3. PubMed ID: 26562628
    [No Abstract]   [Full Text] [Related]  

  • 22. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
    Brastianos PK; Santagata S
    Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
    Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
    Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
    [No Abstract]   [Full Text] [Related]  

  • 25. BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.
    Cancer Discov; 2023 Sep; 13(9):1960. PubMed ID: 37477404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
    Erfurth EM
    J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 31. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endoscopic endonasal approach for craniopharyngioma: the importance of the relationship between pituitary stalk and tumor.
    Dho YS; Kim YH; Se YB; Han DH; Kim JH; Park CK; Wang KC; Kim DG
    J Neurosurg; 2018 Sep; 129(3):611-619. PubMed ID: 28960155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent Radiation and Targeted Therapy for Papillary Craniopharyngioma: A Case Report.
    Shah SN; Kaki PC; Shah SS; Shah SA
    Cureus; 2023 Jun; 15(6):e40190. PubMed ID: 37431357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
    Sidaway P
    Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
    [No Abstract]   [Full Text] [Related]  

  • 38. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
    Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.